Thirteen relapsed or refractory AML patients were treated with the FLA regimen. A complete remission was observed in 54% of cases but the median duration of remission was short (4 months). These results suggest that the FLA regimen is not able to induce a durable complete remission in the poor-risk AML patients.
Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia / Russo, D; Candoni, A; Grattoni, R; Bertone, A; Zaja, Francesco. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 83:3(1998), pp. 281-282.
Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia
ZAJA, Francesco
1998-01-01
Abstract
Thirteen relapsed or refractory AML patients were treated with the FLA regimen. A complete remission was observed in 54% of cases but the median duration of remission was short (4 months). These results suggest that the FLA regimen is not able to induce a durable complete remission in the poor-risk AML patients.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
